Lupin gets USFDA’s nod for Trientine Hydrochloride Capsules USP

22 May 2020 Evaluate
Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2134.55 -16.50 (-0.77%)
01-Feb-2026 10:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1624.35
Dr. Reddys Lab 1215.00
Cipla 1321.00
Zydus Lifesciences 883.50
Lupin 2134.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×